Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.

MLA

Al-Shargi, Amani, et al. “Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.” Biomedicines, vol. 11, no. 11, Nov. 2023. EBSCOhost, https://doi.org/10.3390/biomedicines11113074.

APA

Al-Shargi, A., El Kholy, A. A., Adel, A., Hassany, M., & Shaheen, S. M. (2023). Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. Biomedicines, 11(11). https://doi.org/10.3390/biomedicines11113074

Chicago

Al-Shargi, Amani, Amal A El Kholy, Abdulmoneim Adel, Mohamed Hassany, and Sara M Shaheen. 2023. “Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.” Biomedicines 11 (11). doi:10.3390/biomedicines11113074.